Optas LLC’s Ionis Pharmaceuticals IONS Stock Holding History

Optas LLC’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,034	Closed	-$303K	–	522
2026 Q1	$303K	Buy	+4,034	New	+$318K	0.05%	305

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Optas LLC's IONS Position: Q2 2026 in Review

Optas LLC sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 4,034 shares — an estimated $303K sold.

Optas LLC first reported a position in IONS in Q1 2026 and held it in 1 quarter. The position peaked at $303K in Q1 2026. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Optas LLC reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Optas LLC sold 4,034 Ionis Pharmaceuticals shares in Q2 2026, an estimated $303K.
Optas LLC first reported a position in Ionis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Optas LLC's Ionis Pharmaceuticals position peaked at $303K in Q1 2026.
514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Optas LLC's 13F filing for Q2 2026, filed 21 Jul 2026.